MODULATION OF DRUG RELEASE RATE FROM ELECTROSPUN FIBERS

• US 20120058100A1
• Filed: 11/11/2011
• Published: 03/08/2012
• Est. Priority Date: 10/13/2006
• Status: Abandoned Application

• Current Assignee: Jay C. Sy, Shastri V. Prasad
• Original Assignee: Jay C. Sy, Shastri V. Prasad
• Inventors: Shastri, V. Prasad, Sy, Jay C.
• Application Number:
  US13/295,029
• Publication Number:
  US 20120058100A1
• Time in Patent Office: Days
• US Class Current: 424/94.4
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61P 1/10 Laxatives
• CPC Class Codes: A61P 1/12 Antidiarrhoeals
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

Disclosed are co-electrospun polymeric fibers comprising polymers comprising pharmaceutically active agents and/or biologically active agents and capable of release at a combined release rate. Also disclosed are processes for preparing polymeric fibers capable of release at a combined release rate. Also disclosed are processes of modulating delivery rate of pharmaceutically active agents and/or biologically active agents. Also disclosed are processes of delivering pharmaceutically active agents and/or biologically active agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims

1. A co-electrospun polymeric fiber comprising;

(a) a first polymer comprising a first pharmaceutically active agent or biologically active agent, wherein the first pharmaceutically active agent or biologically active agent is capable of release from the first polymer at a first release rate when the first polymer is not co-electrospun; and

(b) a second polymer comprising a second pharmaceutically active agent or biologically active agent, wherein the second pharmaceutically active agent or biologically active agent is capable of release from the second polymer at a second release rate when the second polymer is not co-electrospun,

wherein the first release rate is greater than the second release rate,

wherein at least one of the first polymer and the second polymer is non-biodegradable, and

wherein the first pharmaceutically active agent or biologically active agent and the second pharmaceutically active agent or biologically active agent are released from the co-electrospun polymeric fibers at a combined release rate between the first release rate and the second release rate.

2. The composition of claim 1, wherein the first polymer and the second polymer are different.

3. The composition of claim 1, wherein the first pharmaceutically active agent or biologically active agent and the second pharmaceutically active agent or biologically active agent are the same.

4. The composition of claim 1, further comprising a third polymer comprising a third pharmaceutically active agent or biologically active agent, wherein the third pharmaceutically active agent or biologically active agent is capable of release from the third polymer at a third release rate when the third polymer is not co-electrospun.

5. The co-electrospun polymeric fiber of claim 1, formed as a bandage.

6. The co-electrospun polymeric fiber of claim 1, formed as an implantable article.

7. The composition of claim 1, wherein the first polymer and the second polymer are the same type of polymer.

8. The composition of claim 1, wherein the first pharmaceutically active agent or biologically active agent and the second pharmaceutically active agent or biologically active agent are different.

9. The composition of claim 1, wherein at least one of the first polymer and the second polymer comprises poly(lactic acid), poly(glycolic acid), or poly(ε

-caprolactone), or a copolymer thereof, or a mixture thereof.

10. The composition of claim 1, wherein at least one of the first polymer and the second polymer comprises polyethylene and/or polyurethane.

11. The composition of claim 1, wherein at least one of the first polymer and the second polymer comprises one or more of poly(lactide-co-glycolide), poly(lactic acid), poly(glycolic acid), poly(glaxanone), poly(orthoesters), poly(pyrolic acid), or poly(phosphazenes)

12. The composition of claim 1, wherein at least one of the first polymer and the second polymer comprises polyurethane.

13. The composition of claim 1, wherein at least one of the first polymer and the second polymer comprises segmented polyurethane selected from poly(ether-urethane), poly(ester-urethane), poly(urea-urethane), poly(carbonate-urethane), and mixtures thereof.

14. The composition of claim 1, wherein the first polymer comprises a non-biodegradable polyurethane.

15. The composition of claim 1, wherein the second polymer comprises a non-biodegradable polyurethane.

16. The composition of claim 1, wherein at least one of the first polymer and the second polymer comprises a non-biodegradable polyurethane and the other of the first polymer and the second polymer comprises a biodegradable polymer.

17. The composition of claim 1, wherein the first polymer comprises the first pharmaceutically active agent selected from a radio sensitizer, a steroid, a xanthine, a beta-2-agonist bronchodilator, an anti-inflammatory agent, an analgesic agent, a calcium antagonist, an angiotensin-converting enzyme inhibitors, a beta-blocker, a centrally active alpha-agonist, an alpha-1-antagonist, an anticholinergic/antispasmodic agent, a vasopressin analogue, an antiarrhythmic agent, an antiparkinsonian agent, an antiangina/antihypertensive agent, an anticoagulant agent, an antiplatelet agent, a sedative, an ansiolytic agent, a peptidic agent, a biopolymeric agent, an antineoplastic agent, a laxative, an antidiarrheal agent, an antimicrobial agent, an antifungal agent, a vaccine, a protein, a nucleic acid, coumarin, albumin, steroids;

xanthines;

beta-2-agonist bronchodilators;

antiinflammatory agents, antiarthritis antiinflammatory agents, non-steroidal antiinflammatory agents;

analgesic agents;

calcium channel blockers;

angiotensin-converting enzyme inhibitors;

beta-blockers;

centrally active alpha-2-agonists;

alpha-1-antagonists;

anticholinergic/antispasmodic agents;

vasopressin analogues;

antiarrhythmic agents;

antiparkinsonian agents;

antiangina agents;

antihypertensive agents;

anticoagulant agents;

antiplatelet agents;

sedatives;

ansiolytic agents;

peptidic and biopolymeric agents;

hirudin, cyclosporin, insulin, somatostatin, protirelin, interferon, desmopres sin, somatotropin, thymopentin, pidotimod, erythropoietin, interleukins, melatonin, granulocyte/macrophage-CSF, heparin;

antineoplastic agents;

laxatives;

antidiarrheal agents;

vaccines;

antimicrobial agents, antifungal agents; and

nucleic acids.

18. The composition of claim 1, wherein the first polymer comprises the first biologically active agent which acts to control infection or inflammation, enhance cell growth and tissue regeneration, control tumor growth, act as an analgesic, promote anti-cell attachment, or enhance bone growth.

19. The composition of claim 1, wherein the second polymer comprises the second pharmaceutically active agent selected from a radio sensitizer, a steroid, a xanthine, a beta-2-agonist bronchodilator, an anti-inflammatory agent, an analgesic agent, a calcium antagonist, an angiotensin-converting enzyme inhibitors, a beta-blocker, a centrally active alpha-agonist, an alpha-1-antagonist, an anticholinergic/antispasmodic agent, a vasopressin analogue, an antiarrhythmic agent, an antiparkinsonian agent, an antiangina/antihypertensive agent, an anticoagulant agent, an antiplatelet agent, a sedative, an ansiolytic agent, a peptidic agent, a biopolymeric agent, an antineoplastic agent, a laxative, an antidiarrheal agent, an antimicrobial agent, an antifungal agent, a vaccine, a protein, a nucleic acid, coumarin, albumin, steroids;

xanthines;

beta-2-agonist bronchodilators;

antiinflammatory agents, antiarthritis antiinflammatory agents, non-steroidal antiinflammatory agents;

analgesic agents;

calcium channel blockers;

angiotensin-converting enzyme inhibitors;

beta-blockers;

centrally active alpha-2-agonists;

alpha-1-antagonists;

anticholinergic/antispasmodic agents;

vasopressin analogues;

antiarrhythmic agents;

antiparkinsonian agents;

antiangina agents;

antihypertensive agents;

anticoagulant agents;

antiplatelet agents;

sedatives;

ansiolytic agents;

peptidic and biopolymeric agents;

hirudin, cyclosporin, insulin, somatostatin, protirelin, interferon, desmopres sin, somatotropin, thymopentin, pidotimod, erythropoietin, interleukins, melatonin, granulocyte/macrophage-CSF, heparin;

antineoplastic agents;

laxatives;

antidiarrheal agents;

vaccines;

antimicrobial agents, antifungal agents; and

nucleic acids.

20. The composition of claim 1, wherein the second polymer comprises the second biologically active agent, which acts to control infection or inflammation, enhance cell growth and tissue regeneration, control tumor growth, act as an analgesic, promote anti-cell attachment, or enhance bone growth.